Vivos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Operational Update
March 30, 2023 16:05 ET
|
Vivos Therapeutics, Inc
2022 and Early 2023 Accomplishments, Including Capital Raise, Cost Reductions and New Technology Acquisition, Set the Stage for Potential 2023 Revenue Growth Management to Host Conference Call...
Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Conference Call
March 30, 2023 07:30 ET
|
Vivos Therapeutics, Inc
LITTLETOWN, Colo., March 30, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical device and technology company that delivers training and a full...
Vivos Therapeutics to Participate in Fireside Chat at the 35th Annual ROTH Conference
March 08, 2023 07:30 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., March 08, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical device and technology company that delivers training and a full line...
Vivos Therapeutics Expands Product Line and Revenue Potential with Acquisition of Product Rights and Patents from Advanced Facialdontics, LLC
March 01, 2023 07:30 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., March 01, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical device and technology company that delivers training and a full line...
Vivos Therapeutics to Present at the Emerging Growth Conference on February 22, 2023
February 21, 2023 16:05 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical technology company focused on developing and commercializing...
Vivos Therapeutics Regains Compliance with Nasdaq Listing Requirements
January 20, 2023 07:30 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Jan. 20, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for...
Vivos Therapeutics Closes $8 Million Private Placement
January 09, 2023 16:45 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for...
Vivos Therapeutics Announces Pricing of $8 Million Private Placement
January 05, 2023 08:10 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for...
Vivos Therapeutics Receives FDA 510(k) Clearance of its Flagship DNA Oral Appliance for Treatment of Obstructive Sleep Apnea
January 04, 2023 07:30 ET
|
Vivos Therapeutics, Inc
LITTLETON, Colo., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for...
Vivos Therapeutics Reports Second and Third Quarter 2022 Financial Results and Provides Operational Update
December 20, 2022 16:15 ET
|
Vivos Therapeutics, Inc
Second and Third Quarter 10-Q Filings Bring Vivos Currenton SEC Filings for Nasdaq Stock Market Purposes Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., Dec. 20, 2022 ...